Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008, 9: 21-
Article
PubMed Central
PubMed
Google Scholar
Wijnen PA, Op den Buijsch RA, Drent M, et al: Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007, 26 (Suppl 2): 211-219.
Article
CAS
PubMed
Google Scholar
Gray IC, Nobile C, Muresu R, Ford S, Spurr NK: A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995, 28: 328-332. 10.1006/geno.1995.1149.
Article
CAS
PubMed
Google Scholar
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994, 270: 414-423.
CAS
PubMed
Google Scholar
Tsao CC, Wester MR, Ghanayem B, et al: Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9. Biochemistry. 2001, 40: 1937-1944. 10.1021/bi001678u.
Article
CAS
PubMed
Google Scholar
Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F: Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999, 254: 628-631. 10.1006/bbrc.1998.9992.
Article
CAS
PubMed
Google Scholar
Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A: The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -- CYP2C9 and warfarin as an example. Br J Clin Pharmacol. 2007, 64: 14-26. 10.1111/j.1365-2125.2007.02850.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Higashi MK, Veenstra DL, Kondo LM, et al: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002, 287: 1690-1698. 10.1001/jama.287.13.1690.
Article
CAS
PubMed
Google Scholar
Miners JO, Birkett DJ: Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998, 45: 525-538. 10.1046/j.1365-2125.1998.00721.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001, 52: 349-355. 10.1046/j.0306-5251.2001.01499.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sim SC, Risinger C, Dahl ML, et al: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006, 79: 103-113. 10.1016/j.clpt.2005.10.002.
Article
CAS
PubMed
Google Scholar
Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005, 5: 6-13. 10.1038/sj.tpj.6500285.
Article
CAS
PubMed
Google Scholar
Aklillu E, Persson I, Bertilsson L, et al: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996, 278: 441-446.
CAS
PubMed
Google Scholar
Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004, 369: 23-37. 10.1007/s00210-003-0832-2.
Article
CAS
PubMed
Google Scholar
Donald PR, Sirgel FA, Venter A, et al: The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis. 2004, 39: 1425-1430. 10.1086/424999.
Article
CAS
PubMed
Google Scholar
Donald PR, Parkin DP, Seifart HI, et al: The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007, 63: 633-639. 10.1007/s00228-007-0305-5.
Article
CAS
PubMed
Google Scholar
Allabi AC, Gala JL, Horsmans Y, et al: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004, 76: 113-118. 10.1016/j.clpt.2004.04.001.
Article
CAS
PubMed
Google Scholar
Bathum L, Skjelbo E, Mutabingwa TK, Madsen H, Horder M, Brosen K: Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol. 1999, 48: 395-401.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gaedigk A, Bhathena A, Ndjountche L, et al: Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J. 2005, 5: 173-182.
Article
PubMed Central
CAS
PubMed
Google Scholar
Herrlin K, Massele AY, Jande M, et al: Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther. 1998, 64: 391-401. 10.1016/S0009-9236(98)90070-4.
Article
CAS
PubMed
Google Scholar
Matimba A, Oluka MN, Ebeshi BU, et al: Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet. 2008, 7: 780-783.
Article
Google Scholar
Weckx S, De Rijk P, Van Broeckhoven C, Del Favero J: SNPbox: Web-based high-throughput primer design from gene to genome. Nucleic Acids Res. 2004, 32: W170-W172. 10.1093/nar/gkh369.
Article
PubMed Central
CAS
PubMed
Google Scholar
Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000, 132: 365-386.
CAS
PubMed
Google Scholar
Weckx S, Del Favero J, Rademakers R, et al: novoSNP, a novel computational tool for sequence variation discovery. Genome Res. 2005, 15: 436-442. 10.1101/gr.2754005.
Article
PubMed Central
CAS
PubMed
Google Scholar
NCBI Single Nucleotide Polymorphism Database (dbSNP): The National Library of Medicine (NLM), [cited April 14 2008], [http://www.ncbi.nlm.nih.gov/SNP]
Raymond M, Rousset F: GENEPOP (Version 1.2): Population Genetics Software for Exact Tests and Ecumenicism. 1995, Laboratoire de Genetique et Environment, [cited August 21 2007], [http://genepop.curtin.edu.au]
Google Scholar
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.
Article
CAS
PubMed
Google Scholar
Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: Server and survey. 2002, European Molecular Biology Laboratory, [cited September 1 2008], [http://genetic.bwh.havard.edu/pph]
Google Scholar
The Uniprot Consortium: The universal protein resource (UniProt). 2008, The Uniprot Consortium, [cited November 27 2007], [http://www.expasy.uniprot.org]
Google Scholar
Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee: Karolinska Institute, [cited February 21 2001], [http://www.cypalleles.ki.se]
Consensus Arylamine N-Acetyltransferase (NAT) Gene Nomenclature: University of Lousiville School of Medicine, [cited October 14 2007], [http://louisville.edu/medschool/pharmacology/NAT.html]
Williams PA, Cosme J, Ward A, Angove HC, Matak VD, Jhoti H: Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003, 424: 464-468. 10.1038/nature01862.
Article
CAS
PubMed
Google Scholar
Gotoh O: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem. 1992, 267: 83-90.
CAS
PubMed
Google Scholar
Rowland P, Blaney FE, Smyth MG, et al: Crystal structure of human cytochrome P450 2D6. J Biol Chem. 2006, 281: 7614-7622. 10.1074/jbc.M511232200.
Article
CAS
PubMed
Google Scholar
Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M: A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol. 1996, 42: 713-719.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M: Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics. 2001, 11: 417-427. 10.1097/00008571-200107000-00005.
Article
CAS
PubMed
Google Scholar
Mizutani T: PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003, 35: 99-106. 10.1081/DMR-120023681.
Article
CAS
PubMed
Google Scholar
Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003, 56: 653-657. 10.1046/j.1365-2125.2003.01937.x.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001, 11: 803-808. 10.1097/00008571-200112000-00008.
Article
CAS
PubMed
Google Scholar
Thompson CA: FDA encourages genetics-aided warfarin dosing. Am J Health Syst Pharm. 2007, 64: 1994-1996.
Article
PubMed
Google Scholar
Furuta T, Shirai N, Kodaira MS, et al: Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007, 81: 521-528. 10.1038/sj.clpt.6100043.
Article
CAS
PubMed
Google Scholar
Goldstein JA, Ishizaki T, Chiba K, et al: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997, 7: 59-64. 10.1097/00008571-199702000-00008.
Article
CAS
PubMed
Google Scholar
Ibeanu GC, Goldstein JA, Meyer U, et al: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther. 1998, 286: 1490-1495.
CAS
PubMed
Google Scholar
Xie HG, Kim RB, Stein CM, Wilkinson GR, Wood AJ: Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin Pharmacol. 1999, 48: 402-408.
Article
PubMed Central
CAS
PubMed
Google Scholar
Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther. 1995, 57: 656-661. 10.1016/0009-9236(95)90228-7.
Article
CAS
PubMed
Google Scholar
Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008, 83: 234-242. 10.1038/sj.clpt.6100406.
Article
CAS
PubMed
Google Scholar
Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007, 17: 93-101.
CAS
PubMed
Google Scholar
Sabbagh A, Darlu P: SNP selection at the NAT2 locus for an accurate prediction of the acetylation phenotype. Genet Med. 2006, 8: 76-85. 10.1097/01.gim.0000200951.54346.d6.
Article
CAS
PubMed
Google Scholar
Walraven JM, Trent JO, Hein DW: Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function. Drug Metab Dispos. 2007, 35: 1001-1007. 10.1124/dmd.107.015040.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wang JF, Wei DQ, Li L, Zheng SY, Li YX, Chou KC: 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun. 2007, 355: 513-519. 10.1016/j.bbrc.2007.01.185.
Article
CAS
PubMed
Google Scholar
de Graaf C, Oostenbrink C, Keizers PH, et al: Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Curr Drug Metab. 2007, 8: 59-77. 10.2174/138920007779315062.
Article
CAS
PubMed
Google Scholar
Bapiro TE, Hasler JA, Ridderstrom M, Masimirembwa CM: The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol. 2002, 64: 1387-1398. 10.1016/S0006-2952(02)01351-5.
Article
CAS
PubMed
Google Scholar
Rogan PK, Svojanovsky S, Leeder JS: Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics. 2003, 13: 207-218. 10.1097/00008571-200304000-00005.
Article
CAS
PubMed
Google Scholar
Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T: MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 2006, 66: 9090-9098. 10.1158/0008-5472.CAN-06-1403.
Article
CAS
PubMed
Google Scholar
Blaisdell J, Mohrenweiser H, Jackson J, et al: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002, 12: 703-711. 10.1097/00008571-200212000-00004.
Article
CAS
PubMed
Google Scholar
Patin E, Harmant C, Kidd KK, et al: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat. 2006, 27: 720-10.1002/humu.9438.
Article
PubMed
Google Scholar
Gage BF, Lesko LJ: Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008, 25: 45-51. 10.1007/s11239-007-0104-y.
Article
CAS
PubMed
Google Scholar
Kirchheiner J: CYP2D6 phenotype prediction from genotype: Which system is the best?. Clin Pharmacol Ther. 2008, 83: 225-227. 10.1038/sj.clpt.6100455.
Article
CAS
PubMed
Google Scholar